Gravity Analytica

Opthea’s Wet AMD Program Featured at Ophthalmology Events

OPT 11.12.2024

SERA-AI Powered Highlights

Drug:sozinibercept-unknown sozinibercept

Diseases:wet age-related macular degeneration

Date of Upcoming Event:2024-11-22

Name of Upcoming Event:17 Congress of the Asia-Pacific Vitreo-Retina Society

Date of Upcoming Event:2024-11-23

Name of Upcoming Event:Ophthalmology Innovation Summit XIV

Full Press Release SEC Filings Our OPT Tweets

About Gravity Analytica

Recent Filings

17Congressof theAsia-Pacific Vitreo-Retina Society,November 22 - 24, 2024

Ophthalmology Innovation Summit XIV,November 23, 2024

MELBOURNE, Australia, andPRINCETON, N.J.,Nov. 12, 2024(GLOBE NEWSWIRE) --Opthea Limited(ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced thatOptheaand sozinibercept will be highlighted during two upcoming Ophthalmology conferences.

Conference details are as follows:

The 17^thCongressof theAsia-Pacific Vitreo-Retina Society(APVRS)

Session:		Rapid Fire 4 – Retina (Medical & Surgical)
Timing:		Friday, November 22, 2024, 3:15 –3:20 PMSingapore time (GMT+8)
Presentation:		Intravitreal Sozinibercept (anti-VEGF-C/-D ‘trap’) Combined with Ranibizumab for the Treatment of Polypoidal Choroidal Vasculopathy: A Predefined Phase 2b Subgroup Analysis
Presenter:		Gregg T. Kokame, MD, MMM, FASRS
Abstract:		https://2024.apvrs.org/abstract/?code=200963

Gregg T. Kokame, MD, MMM, FASRS, will present data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks. Data from this subgroup show that patients treated with a combination of sozinibercept and ranibizumab experienced significantly better visual and anatomic outcomes compared to ranibizumab alone.

APVRS, themedTransforming Retinal Disease Management with Technology, gathers a distinguished international faculty of top specialists in vitreo-retina to share their expertise and experience. The scientific program will focus on exciting areas such as novel surgical innovationsand therapies, and latest advances in imaging and research.

Ophthalmology Innovation Summit XIV (OIS)

Session:		Retina Innovation Showcase
Timing:		Saturday, November 23, 2024,11:15 AM–12:50 PM PT
Presenter:		Frederic Guerard, PharmD, CEO,Opthea
Agenda:		https://ois.net/ois-xiv-agenda/

The Ophthalmology Innovation Summit connects clinical, corporate, and capital leaders to drive the ophthalmic market forward. It showcases groundbreaking advancements and clinical insights in both anterior and posterior ophthalmology segments and offers the opportunity to learn, network and collaborate.

AboutOpthea

Opthea(ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,NCT04757636, and ShORe,NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website atwww.opthea.comand follow us onXandLinkedIn.

Authorized for release to ASX byFrederic Guerard, PharmD, CEO

Investor Inquiries

PJ KelleherLifeSci Advisors, LLCEmail:pkelleher@lifesciadvisors.comPhone: 617-430-7579

Media Inquiries

Silvana Guerci-LenaNorthStream Global PartnersEmail:silvana@nsgpllc.com

Join our email database to receive program updates:Tel: +61 (0) 3 9826 0399, Email:info@opthea.comWeb:www.opthea.com

Source:Opthea Limited

Source: Opthea Limited

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com